Cargando…
FDG uptake, a surrogate of tumour hypoxia?
INTRODUCTION: Tumour hyperglycolysis is driven by activation of hypoxia-inducible factor-1 (HIF-1) through tumour hypoxia. Accordingly, the degree of 2-fluro-2-deoxy-d-glucose (FDG) uptake by tumours might indirectly reflect the level of hypoxia, obviating the need for more specific radiopharmaceuti...
Autores principales: | Dierckx, Rudi Andre, Van de Wiele, Christophe |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Springer-Verlag
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2491423/ https://www.ncbi.nlm.nih.gov/pubmed/18509637 http://dx.doi.org/10.1007/s00259-008-0758-5 |
Ejemplares similares
-
Molecular imaging of hypoxia with radiolabelled agents
por: Mees, Gilles, et al.
Publicado: (2009) -
Repeatability of [(18)F]FDG PET/CT total metabolic active tumour volume and total tumour burden in NSCLC patients
por: Kolinger, Guilherme D., et al.
Publicado: (2019) -
Total (18)F-dopa PET tumour uptake reflects metabolic endocrine tumour activity in patients with a carcinoid tumour
por: Fiebrich, Helle-Brit, et al.
Publicado: (2011) -
FDG uptake is a surrogate marker for defining the optimal biological dose of the mTOR inhibitor everolimus in vivo
por: Cejka, D, et al.
Publicado: (2009) -
Characterization of FDG PET Images Using Texture Analysis in Tumors of the Gastro-Intestinal Tract: A Review
por: Deleu, Anne-Leen, et al.
Publicado: (2020)